Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy - Full Text View

Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy

This study has been completed.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00444665

Purpose

Examine the safety, tolerability and efficacy of travoprost benzalkonium chloride (BAK) free ophthalmic solution compared to either latanoprost or bimatoprost monotherapy.

Condition	Intervention	Phase
Glaucoma	Drug: Travatan-Z	Phase IV

Genetics Home Reference related topics:

early-onset glaucoma

MedlinePlus related topics:

Glaucoma

Drug Information available for:

Travoprost

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study

Official Title:	Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy

Further study details as provided by Alcon Research:

Primary Outcome Measures:

Ocular Surface Disease Symptoms

Secondary Outcome Measures:

Intraocular pressure

Estimated Enrollment:	750
Study Start Date:	May 2007
Primary Completion Date:	August 2007 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Adults with a clinical diagnosis of ocular hypertension, or primary open-angle, pigment dispersion or exfoliation glaucoma in at least one eye (study eye)

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00444665

Locations


United States, Minnesota
	Fridley
	Fridley, Minnesota, United States, 55432

Sponsors and Collaborators

Alcon Research

Investigators


Study Director:	Mark Jasek, PhD	Alcon Research

More Information

Study ID Numbers:	SMA-06-24
First Received:	March 7, 2007
Last Updated:	April 21, 2008
ClinicalTrials.gov Identifier:	NCT00444665
Health Authority:	United States: Institutional Review Board

Keywords provided by Alcon Research:

Glaucoma

Study placed in the following topic categories:

Glaucoma

Eye Diseases

Travoprost

Hypertension

Ocular Hypertension

Additional relevant MeSH terms:

Therapeutic Uses

Cardiovascular Agents

Antihypertensive Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 31, 2008